Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study

Arthritis Rheumatol. 2019 Feb;71(2):281-289. doi: 10.1002/art.40764. Epub 2019 Jan 18.

Abstract

Objective: To determine, in a large, multiethnic/multiracial, prospective inception cohort of patients with systemic lupus erythematosus (SLE), the frequency, attribution, clinical, and autoantibody associations with lupus psychosis and the short- and long-term outcomes as assessed by physicians and patients.

Methods: Patients were evaluated annually for 19 neuropsychiatric (NP) events including psychosis. Scores on the Systemic Lupus Erythematosus Disease Activity Index 2000, the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index, and the Short Form 36 (SF-36) were recorded. Time to event and linear regressions were used as appropriate.

Results: Of 1,826 SLE patients, 88.8% were female and 48.8% were Caucasian. The mean ± SD age was 35.1 ± 13.3 years, the mean ± SD disease duration was 5.6 ± 4.2 months, and the mean ± SD follow-up period was 7.4 ± 4.5 years. There were 31 psychotic events in 28 of 1,826 patients (1.53%), and most patients had a single event (26 of 28 [93%]). In the majority of patients (20 of 25 [80%]) and events (28 of 31 [90%]), psychosis was attributed to SLE, usually either in the year prior to or within 3 years of SLE diagnosis. Positive associations (hazard ratios [HRs] and 95% confidence intervals [95% CIs]) with lupus psychosis were previous SLE NP events (HR 3.59 [95% CI 1.16-11.14]), male sex (HR 3.0 [95% CI 1.20-7.50]), younger age at SLE diagnosis (per 10 years) (HR 1.45 [95% CI 1.01-2.07]), and African ancestry (HR 4.59 [95% CI 1.79-11.76]). By physician assessment, most psychotic events resolved by the second annual visit following onset, in parallel with an improvement in patient-reported SF-36 summary and subscale scores.

Conclusion: Psychosis is an infrequent manifestation of NPSLE. Generally, it occurs early after SLE onset and has a significant negative impact on health status. As determined by patient and physician report, the short- and long-term outlooks are good for most patients, although careful follow-up is required.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Age Factors
  • Antibodies, Anticardiolipin / immunology
  • Autoantibodies / immunology
  • Cohort Studies
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Linear Models
  • Lupus Coagulation Inhibitor / immunology
  • Lupus Erythematosus, Systemic / epidemiology
  • Lupus Erythematosus, Systemic / immunology
  • Lupus Vasculitis, Central Nervous System / epidemiology*
  • Lupus Vasculitis, Central Nervous System / immunology
  • Male
  • Middle Aged
  • Proportional Hazards Models
  • Prospective Studies
  • Psychotic Disorders / epidemiology*
  • Psychotic Disorders / immunology
  • Receptors, N-Methyl-D-Aspartate / immunology
  • Sex Factors
  • Young Adult
  • beta 2-Glycoprotein I / immunology

Substances

  • Antibodies, Anticardiolipin
  • Autoantibodies
  • Lupus Coagulation Inhibitor
  • Receptors, N-Methyl-D-Aspartate
  • beta 2-Glycoprotein I